Medication Summary
- For noncholera Vibrio infections other than gastroenteritis, the combination of ceftazidime and doxycycline or an antipseudomonal penicillin (eg, ticarcillin and clavulanate, piperacillin and tazobactam) is the therapy of choice.
- Alternative antibiotics include cefotaxime and/or fluoroquinolones. Although in vitro testing demonstrates that Vibrio species are sensitive to aminoglycosides, the use of aminoglycosides may be associated with toxicities above those observed with other agents.
- Another alternative regimen with documented synergism in vivo study on mice is cefotaxime and minocycline.[24]
- In a retrospective chart review of 93 patients hospitalized with serious Vibrio infections, the combination of a third-generation cephalosporin and tetracycline or its analogue was an independent factor for lower mortality (OR, 0.337; 95% CI, 0.007-0.192; P < .001).[20]
- Tigecycline, a novel glycylcycline, has a potent in vitro antimicrobial effect against Vibrio species. Other newer antibiotics such as daptomycin and linezolid that were approved for the treatment of serious skin and soft-tissue infections have not been studied in serious Vibrio infections. Therefore, the authors do not currently recommend the use of these antibiotics in the treatment of serious Vibrio infections.
- Adjuvant therapy: Recombinant human activated protein C (drotrecogin alfa activated) has been used as an adjuvant therapy in patients with severe sepsis who scored 25 or more on the Acute Physiology and Chronic Health Evaluation (APACHE II). A few patients with V vulnificus sepsis who were successfully treated with antibiotics, surgical debridement, and recombinant human activated protein C were reported. In view of serious bleeding associated with the continuous infusion of recombinant human activated protein C and the potential requirement for repeated surgical debridement in patients with V vulnificus sepsis, routine use of this adjuvant therapy is not recommended.[25]
Antibiotics
Class Summary
Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting. Antibiotic combinations are usually recommended for serious gram-negative bacillary infections. This approach ensures coverage for a broad range of organisms and polymicrobial infections. In addition, resistance from bacterial subpopulations is prevented, and additive or synergistic effects are provided. Once organisms and sensitivities are known, the use of antibiotic monotherapy is recommended.
Doxycycline (Bio-Tab, Doryx, Vibramycin, Doxy)
Inhibits protein synthesis and, thus, bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria.
Piperacillin and tazobactam (Zosyn)
Antipseudomonal penicillin plus beta-lactamase inhibitor. Inhibits biosynthesis of cell wall mucopeptide and is effective during stage of active multiplication.
Ticarcillin and clavulanate (Timentin)
Inhibits biosynthesis of cell wall mucopeptide and is effective during stage of active growth. Antipseudomonal penicillin plus beta-lactamase inhibitor provides coverage against most gram-positive, gram-negative, and anaerobic bacteria.
Ciprofloxacin (Cipro, Ciloxan)
Fluoroquinolone with activity against pseudomonads, streptococci, MRSA, Staphylococcus epidermidis, and most gram-negative organisms but no activity against anaerobes. Inhibits bacterial DNA synthesis and, consequently, growth.
Cefotaxime (Claforan)
For septicemia and treatment of gynecologic infections caused by susceptible organisms. Arrests bacterial cell wall synthesis, which in turn inhibits bacterial growth. Third-generation cephalosporin with gram-negative spectrum. Lower efficacy against gram-positive organisms.
2011 Estimates of foodborne illness in the united states. Available at http://www.cdc.gov/foodborneburden.
Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, et al. Foodborne illness acquired in the United States--major pathogens. Emerg Infect Dis. Jan 2011;17(1):7-15. [Medline].
3. Vital Signs: Incidence and Trends of Infection with Pathogens Transmitted Commonly Through Food --- Foodborne Diseases Active Surveillance Network, 10 U.S. Sites, 1996—2010. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6022a5.htm?s_cid=mm6022a5_w.
Marano NN, Daniels NA, Easton AN, McShan A, Ray B, Wells JG. A survey of stool culturing practices for vibrio species at clinical laboratories in Gulf Coast states. J Clin Microbiol. Jun 2000;38(6):2267-70. [Medline].
Dechet AM, Yu PA, Koram N, Painter J. Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997-2006. Clin Infect Dis. Apr 1 2008;46(7):970-6. [Medline].
Centers for Disease Control and Prevention (CDC). Vibrio illnesses after Hurricane Katrina--multiple states, August-September 2005. MMWR Morb Mortal Wkly Rep. Sep 23 2005;54(37):928-31. [Medline].
Shapiro RL, Altekruse S, Hutwagner L. The role of Gulf Coast oysters harvested in warmer months in Vibrio vulnificus infections in the United States, 1988-1996. Vibrio Working Group. J Infect Dis. Sep 1998;178(3):752-9. [Medline].
Brennt CE, Wright AC, Dutta SK. Growth of Vibrio vulnificus in serum from alcoholics: association with high transferrin iron saturation. J Infect Dis. Nov 1991;164(5):1030-2. [Medline].
Hor LI, Chang TT, Wang ST. Survival of Vibrio vulnificus in whole blood from patients with chronic liver diseases: association with phagocytosis by neutrophils and serum ferritin levels. J Infect Dis. Jan 1999;179(1):275-8. [Medline].
Miyoshi S, Nakazawa H, Kawata K, Tomochika K, Tobe K, Shinoda S. Characterization of the hemorrhagic reaction caused by Vibrio vulnificus metalloprotease, a member of the thermolysin family. Infect Immun. Oct 1998;66(10):4851-5. [Medline].
Shao CP, Hor LI. Metalloprotease is not essential for Vibrio vulnificus virulence in mice. Infect Immun. Jun 2000;68(6):3569-73. [Medline].
Hilton T, Rosche T, Froelich B, Smith B, Oliver J. Capsular polysaccharide phase variation in Vibrio vulnificus. Appl Environ Microbiol. Nov 2006;72(11):6986-93. [Medline].
Lee SE, Kim SY, Kim CM, Kim MK, Kim YR, Jeong K. The pyrH gene of Vibrio vulnificus is an essential in vivo survival factor. Infect Immun. Jun 2007;75(6):2795-801. [Medline].
Wong TW, Wang YY, Sheu HM, Chuang YC. Bactericidal effects of toluidine blue-mediated photodynamic action on Vibrio vulnificus. Antimicrob Agents Chemother. Mar 2005;49(3):895-902. [Medline].
Shirai H, Ito H, Hirayama T, Nakamoto Y, Nakabayashi N, Kumagai K. Molecular epidemiologic evidence for association of thermostable direct hemolysin (TDH) and TDH-related hemolysin of Vibrio parahaemolyticus with gastroenteritis. Infect Immun. Nov 1990;58(11):3568-73. [Medline].
Nishibuchi M, Fasano A, Russell RG, Kaper JB. Enterotoxigenicity of Vibrio parahaemolyticus with and without genes encoding thermostable direct hemolysin. Infect Immun. Sep 1992;60(9):3539-45. [Medline].
Vibrio parahaemolyticus infections associated with consumption of raw shellfish--three states, 2006. MMWR Morb Mortal Wkly Rep. Aug 11 2006;55(31):854-6. [Medline].
Osaka K, Komatsuzaki M, Takahashi H, Sakano S, Okabe N. Vibrio vulnificus septicaemia in Japan: an estimated number of infections and physicians' knowledge of the syndrome. Epidemiol Infect. Oct 2004;132(5):993-6. [Medline].
Haq SM, Dayal HH. Chronic liver disease and consumption of raw oysters: a potentially lethal combination--a review of Vibrio vulnificus septicemia. Am J Gastroenterol. May 2005;100(5):1195-9. [Medline].
Liu JW, Lee IK, Tang HJ, Ko WC, Lee HC, Liu YC. Prognostic Factors and Antibiotics in Vibrio vulnificus Septicemia. Arch Intern Med. Oct 23 2006;166(19):2117-23. [Medline].
Dadisman TA Jr, Nelson R, Molenda JR. Vibrio parahaemolyticus gastroenteritis in Maryland. I. Clinical and epidemiologic aspects. Am J Epidemiol. Dec 1972;96(6):414-26. [Medline].
Howard RJ, Lieb S. Soft-tissue infections caused by halophilic marine vibrios. Arch Surg. Feb 1988;123(2):245-9. [Medline].
Klontz KC, Lieb S, Schreiber M. Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981-1987. Ann Intern Med. Aug 15 1988;109(4):318-23. [Medline].
Chuang YC, Ko WC, Wang ST, Liu JW, Kuo CF, Wu JJ. Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection. Antimicrob Agents Chemother. Jun 1998;42(6):1319-22. [Medline].
Anand RG, Lopez FA, deBoisblanc B. Vibrio vulnificus sepsis successfully treated with antibiotics, surgical debridement, and recombinant human activated protein C. J La State Med Soc. May-Jun 2004;156(3):130-3; quiz 133. [Medline].
Mouzin E, Mascola L, Tormey MP. Prevention of Vibrio vulnificus infections. Assessment of regulatory educational strategies. JAMA. Aug 20 1997;278(7):576-8. [Medline].
Centers for Disease Control and Prevention (CDC). Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food--selected sites, United States, 2003. MMWR Morb Mortal Wkly Rep. Apr 30 2004;53(16):338-43. [Medline].
Hiransuthikul N, Tantisiriwat W, Lertutsahakul K, Vibhagool A, Boonma P. Skin and soft-tissue infections among tsunami survivors in southern Thailand. Clin Infect Dis. Nov 15 2005;41(10):e93-6. [Medline].
Hlady WG, Klontz KC. The epidemiology of Vibrio infections in Florida, 1981-1993. J Infect Dis. May 1996;173(5):1176-83. [Medline].
Hollis DG, Weaver RE, Baker CN. Halophilic Vibrio species isolated from blood cultures. J Clin Microbiol. Apr 1976;3(4):425-31. [Medline].
Scallan E, Griffin PM, Angulo FJ, Tauxe RV, Hoekstra RM. Foodborne illness acquired in the United States--unspecified agents. Emerg Infect Dis. Jan 2011;17(1):16-22. [Medline].
Summary of Notifiable Diseases in United States, 2009. Available at http://www.cdc.gov/mmwr/pdf/wk/mm5853.pdf.
| Infection Type | Noncholera Vibrio Species | Cytotoxins/Enzymes |
| Gastroenteritis | V parahaemolyticus Non-01 V cholerae Vibrio fluvialis V mimicus Vibrio furnissii Vibrio hollisae Vibrio alginolyticus V vulnificus | Cytotoxin Hemolysin |
| Wound infection | V alginolyticus V vulnificus Non-01 V cholerae Vibrio damsela Vibrio carchariae V fluvialis V parahaemolyticus V mimicus | Protease Hemolysin Lipase DNAase Cytolysin |
| Septicemia | V vulnificus V fluvialis V damsela Non-01 V cholerae Vibrio cincinnatiensis | Proteases Endotoxic lipopolysaccharide |
| Vibrio Species | Gastroenteritis (%) | Wound Infection (%) | Septicemia (%) | Miscellaneous (%) |
| V parahaemolyticus | 59 | 34 | 5 | 2 |
| V vulnificus | 5 | 45 | 43 | 7 |
| Non-01 V cholerae | 67 | 9 | 15 | … |
| V alginolyticus | 5-12 | 71 | 1 | 10-15 |
| V mimicus | 85 | 3 | 3 | … |
| V fluvialis | 73 | 10 | 6 | … |
| V damsela | Rare | >95 | Rare | … |
| V furnissii | >90 | Rare | Rare | … |
| Vibrio metschnikovii | Common | Rare | Rare | … |
| V hollisae | 85 | 7 | 5 | … |
| V cincinnatiensis | Rare | Rare | Rare | Meningitis |
| Clinical Presentation | Symptoms (Frequency) |
| Gastroenteritis | Diarrhea (100%) Abdominal cramps (89%) Nausea (76%) Vomiting (55%) Fever (47%) Bloody stools (29%) Headache (24%) Myalgia (24%) |
| Wound infection | Swelling (100%) Pain (100%) Erythema (100%) Bullae (30-50%) Necrosis (30-50%) Gangrene (< 10%) |
| Septicemia | Fever (>90%) Hypothermia (< 10%) Hypotension (100%) Tachycardia (80-90%) Shock (50-70%) Bullae (80-100%) Acute respiratory distress syndrome (< 5%) Multiple organ dysfunction (30-50%) |
Print
